Illumina (ILMN) Q2 2026 Earnings Call Transcript
Thursday, July 30, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Head of Investor Relations - Conor McNamara Chief Executive Officer - Jacob Thaysen Chief Financial Officer - Ankur Dhingra TAKEAWAYS Total Revenue -- $1.16 billion, representing a 9.5% increase year over year driven by clinical market demand and the NovaSeq X expansion. Rest of World Organic Revenue -- Increased 8.1% year over year, exceeding the high end of management's previous guidance.
How this was made
The 30-second read
Why it matters
The most tradable elements are the raised FY 2026 revenue and EPS ranges, the Q3 revenue and EPS outlook, and the operational confirmation that NovaSeq X is becoming the dominant platform for volumes and revenue.
Market read
Guidance increases plus NovaSeq X installed-base and conversion metrics are likely to drive estimate revisions and near-term positioning, while research consumables weakness is a key risk to monitor.
What to watch
The call notes customers remain cautious and research consumables declined 7% year over year, which could cap upside if clinical conversion to NovaSeq X slows versus the 80%-85% target.
Background
Illumina reported Q2 2026 results and provided updated full-year and third-quarter guidance, alongside operational metrics for NovaSeq X transition and consumables demand.
Ticker impact
Illumina raised FY 2026 revenue guidance to $4.60B-$4.64B and FY non-GAAP EPS to $5.30-$5.40 after Q2 results and NovaSeq X momentum.
Likely near-term positive bias as raised guidance and higher installed-base conversion can support estimates, partially offset by continued weakness in research and applied consumables.
The article discloses multiple concrete, decision-relevant datapoints: Q2 revenue/EPS beats, raised FY and Q3 guidance ranges, NovaSeq X placements and volume conversion targets, and a specific margin headwind from freight and memory costs.
Market effects
Signals continued demand durability in clinical sequencing while research and academic budgets remain sensitive to macro and funding conditions.
U.S.-Canada clinical growth is highlighted as the primary driver, implying regional strength may matter for near-term demand expectations.
Rest-of-world organic growth guidance increased, suggesting broader international momentum beyond Greater China.
Counterpoint
Raised guidance may still be vulnerable if research and applied consumables weakness persists or if freight and memory cost pressures re-accelerate.
Key entities
- companyIllumina
Reported Q2 2026 results and raised FY 2026 guidance, citing clinical demand strength and NovaSeq X expansion.
- executiveJacob Thaysen
CEO who discussed customer caution and expectations for clinical momentum.
- executiveAnkur Dhingra
CFO who discussed margin impacts from freight and memory costs and inventory actions.
